Eli Lilly CEO: GLP-1 oral pill category is ‘expansionary’ and is ‘not cannibalizing Zepbound’

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

David Ricks, Eli Lilly chairman and CEO, joins ‘Squawk Box’ to discuss second-quarter earnings and revenue that easily beat estimates and hiked its full-year sales outlook, drug pricing, how oral therapies have expanded the market, and more.